胆安合剂治疗胆囊术后综合征临床观察-《西部中医药》

文章信息/Info

Title:: Clinical Study on Dan′an Mixture in the Treatment for Postcholecystectomy Syndrome

Author(s):: FAN Wen, LI Yunshan, XU Kun, BING Qiang; The First People′s Hospital of Lanzhou City, Lanzhou 730050, China

摘要:: 目的：观察胆安合剂治疗胆囊切除术后综合征(postcholecystectomy syndrome，PCS)的临床疗效。方法：将120例患者根据治疗方法的不同分为观察组及对照组，每组60例。观察组口服胆安合剂，每次125 mL，每日2次，餐后半小时热服。对照组口服消炎利胆片，4粒/次，每日3次，餐前半小时口服。两组均连续服用1个月。比较两组临床疗效和治疗前后症状积分的变化及不良反应。结果：总有效率观察组为93.3%(56/60)，对照组为73.3%(44/60)，两组比较差异有统计学意义(P＜0.05)。腹痛、腹胀、右肩背胀、消化不良、食欲减退等症状评分治疗前后两组组内比较，差异有统计学意义(P＜0.05)；治疗后两组组间比较差异也有统计学意义(P＜0.05)。两组服药期间各有8例患者出现轻度腹泻，经减少服药剂量后自行缓解，无其他不良反应。结论：胆安合剂治疗PCS可明显改善临床症状，提高患者生活质量。

Abstract:: Objective: To observe clinical effects of Dan′an mixture in the treatment for postcholecystectomy syndrome (PCS). Methods: According to different therapeutic methods, 120 patients were allocated to the observation group and the control group, 60 cases each group, the observation group took Dan′an mixture, 125 mL each time, twice each day, taking half an hour after the meal, and the control group took Xiaoyan Lidan tablets, four pills each time, three times each day, taking half an hour before the meal. Both groups were treated for one month consecutively. To compare clinical effects, symptom scores and side effects before and after treating. Results: Total effective rate of the observation group was 93.3%(56/60), higher than 73.3%(44/60) of the control group, and the difference had statistical meaning (P＜0.05). The difference had statistical meaning in the scores of abdominal pain, abdominal distension, right shoulder bulging, dyspepsia and loss of appetite within two groups before and after treating (P＜0.05), and these were the significant differences between both groups after treating (P＜0.05). There were each eight patients showing slight diarrhea in both groups during the medication period, they were relieved after the dose reduced, and no other side effects happen. Conclusion: Dan′an mixture could improve clinical symptoms and raise quality of life in PCS patients notably.